[HTML][HTML] CCR6 is required for epidermal trafficking of γδ-T cells in an IL-23-induced model of psoriasiform dermatitis

T Mabuchi, TP Singh, T Takekoshi, G Jia, X Wu… - Journal of Investigative …, 2013 - Elsevier
T Mabuchi, TP Singh, T Takekoshi, G Jia, X Wu, MC Kao, I Weiss, JM Farber, ST Hwang
Journal of Investigative dermatology, 2013Elsevier
A subset of CC chemokine receptor-6+(CCR6+), γδ-low (GDL) T cells that express Th17
cytokines in mouse skin participates in IL-23-induced psoriasiform dermatitis. We use CCR6-
deficient (knockout, KO) and wild-type (WT) mice to analyze skin trafficking patterns of GDL T
cells and function-blocking mAbs to determine the role of CCR6 in IL-23-mediated
dermatitis. Herein, CCL20 was highly upregulated in IL-23-injected WT mouse ear skin as
early as 24 hours after initial treatment, and large numbers of CCR6+ cells were observed in …
A subset of CC chemokine receptor-6+ (CCR6+), γδ-low (GDL) T cells that express Th17 cytokines in mouse skin participates in IL-23-induced psoriasiform dermatitis. We use CCR6-deficient (knockout, KO) and wild-type (WT) mice to analyze skin trafficking patterns of GDL T cells and function-blocking mAbs to determine the role of CCR6 in IL-23-mediated dermatitis. Herein, CCL20 was highly upregulated in IL-23-injected WT mouse ear skin as early as 24 hours after initial treatment, and large numbers of CCR6+ cells were observed in the epidermis of IL-23-injected WT mice. Anti-CCL20 mAbs reduced psoriasiform dermatitis and blocked recruitment of GDL T cells to the epidermis. In CCR6 KO mice, GDL T cells failed to accumulate in the epidermis after IL-23 treatment, but the total numbers of GDL T cells in the dermis of WT and CCR6 KO mice were equivalent. There was an ∼70% reduction in the proportion of IL-22+ GDL T cells in the dermis of CCR6 KO mice (vs WT mice), suggesting that effector function and epidermal recruitment of GDL T cells are impaired in CCR6-deficient mice. Thus, these data show that CCR6 regulates epidermal trafficking of γδ-T-cell subsets in the skin and suggest the potential of CCR6 as a therapeutic target for psoriasis.
Elsevier